FDA to Merck: Mevacor OTC not approvable

Share this article:

The FDA needs to see additional data from Merck before approving an OTC version of the drugmaker's cholesterol-lowering drug Mevacor (lovastatin).

The agency requested the data along with revised labeling for the drug in a non-approvable letter sent to Merck late last week.

“We're evaluating the conditions outlined in the agency's response to determine a path forward for Mevacor OTC,” Merck VP, global OTC regulatory and scientific affairs, Edwin Hemwall said in a statement.

In December, an FDA advisory panel recommended against approval of cholesterol-lowering Mevacor without a prescription by a 10 to 2 vote.

The rejection of Mevacor OTC marks the third time a global drugmaker has failed to win FDA approval for the drug's non-prescription status.

Merck has twice failed before to convince the FDA – once in 2000 and once in 2005 – that patients could safely use Mevacor without a doctor's prescription.

Mevacor lost US patent protection in 2001, with Merck and prospective marketing partner Johnson & Johnson trying to secure OTC status in the years to follow.
 
The UK became the first nation to approve an OTC statin in 2004, allowing the sale of a 10 mg version of simvastatin, which is marketed as Zocor Heart-Pro by Merck.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...